Sunil Shah
Executive Chairman @ Alevin Therapeutics
Cambridge, United Kingdom
Sunil Shah is a seed investor at Alevin Therapeutics in Cambridge focused on Biotechnology and Health Care. Sunil Shah is based out of Newcastle, Newcastle upon Tyne and is the Chair of the Board of Atelerix and also CEO, Co-Founder of o2h group. Sunil previously worked at India-UK Cancer Research Initiative as an Advisory Panel Member. Sunil Shah attended the University of Cambridge.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 64%
Last updated:
For AI agents: llms.txt
Industries Sunil Shah invests in
Stages Sunil Shah invests in
Countries Sunil Shah invests in
Investment Focus
Industry
- Biotechnology 11 (79%)
- Health Care 10 (71%)
- Pharmaceutical 4 (29%)
- Biopharma 3 (21%)
- Medical 2 (14%)
Stage
- Seed 10 (71%)
- Venture - Series Unknown 3 (21%)
- Funding Round 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Monument Therapeutics
|
Monument Therapeutics is a biotechnology company intended to develop drugs to treat serious diseases of the central nervous system. | $1.1M / Venture - Series Unknown / Feb 25, 2025 | |
Atelerix
|
Atelerix has a transformative technology for the storage and transport of viable cells at room temperature, overcoming the barriers and limitations presented by the current need for cryo-shipping. We do this using our patented process of encapsulating the cells in a natural hydrogel for safe shipment and storage. The cells can be recovered whenneeded by the addition of a gentle, cell-friendly buffer. This means: Predictability and reliability in drug discovery models and for cells used as therapies Customers can use cells and assays immediately on arrival No need for cryopreservation, nor need for cytotoxic or animal-derived supplements Cells retain their natural state and are not damaged nor altered | $933.1K / Jan 28, 2025 | |
Pencil Biosciences
|
Pencil Biosciences aims to develop a novel, programmable genome-modulation tool that overcomes the challenges associated with the technologies currently available. | $7.3M / Seed / Sep 28, 2023 | |
Five Alarm Bio
|
Five Alarm Bio is a drug discovery company. Five Alarm intends to use discoveries to provide secure and efficient remedies for a variety of age-related illnesses and limitations. Five Alarm Bio is creating a small molecule strategy to strengthen the body's defense against aging. | $603.1K / Seed / Feb 27, 2023 | |
Alevin Therapeutics
|
Alevin Therapeutics is creating breakthrough approaches to safe and effective medicines for patients with life-threatening diseases. | Seed / Jul 29, 2022 | |
Neurocentrx
|
Developing medicines to treat patients with neurological conditions. Our interests lie in psychiatric, mental health and mood disorders, neurodegenerative diseases and complex pain management in cancer and palliative care. Our focus is to provide existing approved drugs in new and improved formats for patients - through reformulation, reindication,clinical development and product in-licensing. | Venture - Series Unknown / May 12, 2022 | |
Xploro
|
Xploro is an award-winning and clinically validated health information platform that uses augmented reality, gameplay, and artificial intelligence to deliver health information to young patients, in a way that makes them feel empowered, engaged and informed, whilst having fun at the same time. | Seed / Feb 16, 2022 | |
Tay Therapeutics
|
Tay Therapeutics is a drug discovery company that develops the next generation of topical and oral therapies for inflammatory conditions. | $2.2M / Seed / Nov 02, 2021 | |
BiVictriX Therapeutics
|
BiVictriX is a drug discovery and development company. Their services include oncology, haematological malignancies, bispecific ADC therapeutics, biotherapeutics, immunotherapy, antibody research, and drug development. | Venture - Series Unknown / Aug 05, 2021 | |
Kuano
|
Kuano provides innovative quantum and AI solutions for drug discovery and design. It offers a discovery platform that combines target quantum mapping and AI-led chemistry to enable the faster development of better drug candidates. | $1.4M / Seed / Jul 08, 2021 | |
| See all 14 investments → | |||
Co-Investors
About Alevin Therapeutics
Alevin Therapeutics is creating breakthrough approaches to safe and effective medicines for patients with life-threatening diseases.
Alevin Therapeutics Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Sunil Shah
Executive Chairman
|
|||
Sunil Shah
Executive Chairman
|
|||
3 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Sunil Shah invest in?
Sunil Shah invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Seed and Venture - Series Unknown stage. Most of the 14 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Sunil Shah last invest?
The most recent investment recorded for Sunil Shah closed in Feb 2025. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
